Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-expressing”

217 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 217 results

Large-scale testing (Phase 3)Looking for participantsNCT06989112
What this trial is testing

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Who this might be right for
Endometrial Cancer
AstraZeneca 600
Not applicableStudy completedNCT06386263
What this trial is testing

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

Who this might be right for
Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer+1 more
AstraZeneca 22
Large-scale testing (Phase 3)Not Yet RecruitingNCT06561607
What this trial is testing

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 542
Large-scale testing (Phase 3)Ended earlyNCT00272987
What this trial is testing

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 63
Large-scale testing (Phase 3)Looking for participantsNCT06467357
What this trial is testing

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer
AstraZeneca 620
Early research (Phase 1)UnknownNCT06154343
What this trial is testing

GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd. 150
Testing effectiveness (Phase 2)Study completedNCT05400915
What this trial is testing

Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients

Who this might be right for
Gastric Cancer
Yonsei University 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Early research (Phase 1)Study completedNCT00250419
What this trial is testing

V930 First in Man (FIM) Study (V930-002)(COMPLETED)

Who this might be right for
Cancers Expressing HER-2 and/or CEA
Merck Sharp & Dohme LLC 26
Testing effectiveness (Phase 2)UnknownNCT05349409
What this trial is testing

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Who this might be right for
Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 212
Early research (Phase 1)Active Not RecruitingNCT02792114
What this trial is testing

T-Cell Therapy for Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic HER2-negative Breast
Memorial Sloan Kettering Cancer Center 186
Early research (Phase 1)Study completedNCT03383692
What this trial is testing

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

Who this might be right for
Neoplasm Metastasis
Daiichi Sankyo Co., Ltd. 40
Large-scale testing (Phase 3)Looking for participantsNCT06221748
What this trial is testing

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd. 90
Not applicableLooking for participantsNCT06877416
What this trial is testing

Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer

Who this might be right for
Antibody-drug ConjugatesHER2-low Breast CancerBreast Neoplasms
Sun Yat-sen University 700
Early research (Phase 1)Active Not RecruitingNCT05311397
What this trial is testing

A166 in Patients With Advanced Solid Malignant Tumors

Who this might be right for
Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 120
Testing effectiveness (Phase 2)Looking for participantsNCT06026657
What this trial is testing

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8HER2-Negative Breast Carcinoma
Margaret Gatti-Mays 42
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07142200
What this trial is testing

A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer
RenJi Hospital 45
Testing effectiveness (Phase 2)Study completedNCT04205630
What this trial is testing

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Who this might be right for
Endometrial Cancer
Byondis B.V. 64
Testing effectiveness (Phase 2)Looking for participantsNCT06413745
What this trial is testing

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Who this might be right for
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd. 65
Testing effectiveness (Phase 2)Looking for participantsNCT06411457
What this trial is testing

SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 20
Load More Results